96092 20210902121813.0 doi 10.1093/ecco-jcc/jjz180 sideral 118291 ART-2020-118291 eng Torres, J. ECCO guidelines on therapeutics in Crohn's disease: Medical treatment 2020 Access copy available to the general public Unrestricted Crohn’s disease [CD] is a chronic inflammatory bowel disease [IBD] that can result in progressive bowel damage and disability1. CD can affect individuals of any age, from children to the elderly, 2, 3 and may cause significant morbidity and impact on quality of life. Up to one-third of patients present with complicated behaviour [strictures, fistula, or abscesses] at diagnosis4. Most patients over time will develop a complication, with roughly 50% of patients requiring surgery within 10 years of diagnosis5-7. As the precise aetiology of CD remains unknown, a curative therapy is not yet available8. Several agents are available for the medical treatment of CD. Medical agents include mesalazine [5-ASA], locally active steroids [such as budesonide], systemic steroids, thiopurines such as azathioprine [AZA] and mercaptopurine [MP], methotrexate [MTX], and biological therapies [such as anti-TNF, anti-integrins, and anti-IL12/23]. The European Crohn’s and Colitis Organisation [ECCO] produces and regularly updates several guidelines aimed at providing evidence-based guidance on critical aspects of IBD care to all healthcare professionals who manage patients with IBD. To provide high-quality evidence-based recommendations on medical and surgical treatment in CD, ECCO decided to develop these guidelines by adopting the GRADE [Grading of Recommendations Assessment, Development, and Evaluation] approach9. GRADE is a systematic process for developing guidelines that addresses how to frame the healthcare questions, summarize the evidence, .. info:eu-repo/semantics/openAccess All rights reserved http://www.europeana.eu/rights/rr-f/ 9.071 2020 GASTROENTEROLOGY & HEPATOLOGY 14 / 92 = 0.152 2020 Q1 T1 3.277 2020 Medicine (miscellaneous) 2020 Q1 Gastroenterology 2020 Q1 info:eu-repo/semantics/review info:eu-repo/semantics/acceptedVersion Bonovas, S. Doherty, G. Kucharzik, T. Gisbert, J.P. Raine, T. Adamina, M. Armuzzi, A. Bachmann, O. Bager, P. Biancone, L. Bokemeyer, B. Bossuyt, P. Burisch, J. Collins, P. El-Hussuna, A. Ellul, P. Frei-Lanter, C. Furfaro, F. Gingert, C. Gionchetti, P. Gomollon, F. Universidad de Zaragoza (orcid)0000-0003-0076-3529 González-Lorenzo, M. Gordon, H. Hlavaty, T. Juillerat, P. Katsanos, K. Kopylov, U. Krustins, E. Lytras, T. Maaser, C. Magro, F. Kenneth Marshall, J. Myrelid, P. Pellino, G. Rosa, I. Sabino, J. Savarino, E. Spinelli, A. Stassen, L. Uzzan, M. Vavricka, S. Verstockt, B. Warusavitarne, J. Zmora, O. Fiorino, G. on, behalf, of, the, European, Crohn''s, and, Colitis, Organisation, [ECCO] 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 14, 1 (2020), 4-22 J. Crohns Colitis Journal of Crohn's & colitis 1873-9946 607630 http://zaguan.unizar.es/record/96092/files/texto_completo.pdf Postprint 664411 http://zaguan.unizar.es/record/96092/files/texto_completo.jpg?subformat=icon icon Postprint oai:zaguan.unizar.es:96092 articulos driver 2021-09-02-10:02:37 ARTICLE